GlassScriptPhysician profile
Rachel E Bergang
NPI 1073516332
$2,410.44
in general payments reported to CMS, 2019-2025
10 companies · $354 in 2025
The $354 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $450 · 2021: $323 · 2022: $325 · 2023: $139 · 2024: $77.28 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,474.77 | 2019-2022 | |
| Fidia Pharma USA INC. | $194.72 | 2019-2025 | Hymovis |
| Pacira Pharmaceuticals Incorporated | $191.10 | 2025 | Zilretta |
| Depuy Synthes Sales INC. | $185.63 | 2019-2025 | Monovisc |
| Bioventus LLC | $119.78 | 2019-2025 | Gelsyn-3, Durolane |
| Abbvie INC. | $65.37 | 2023 | Qulipta, Ubrelvy |
| Pacira Therapeutics, INC. | $59.61 | 2019 | |
| Boston Scientific Corporation | $54.25 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Djo, LLC | $43.97 | 2025 | Donjoy |
| Ibsa Pharma INC. | $21.24 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bergang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.